| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Romiplostim |
| Brand | Nplate® |
| Indication | Is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). |
| Assessment Process | |
| Rapid review commissioned | 16/06/2019 |
| Rapid review completed | 18/07/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of romiplostim compared with the current standard of care. |
The Applicant is seeking reimbursement under the High Tech Drug Arrangements.
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.